Scientists track immune cells to unlock immunotherapy secrets in kidney and bladder cancers
NCT ID NCT02978118
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how immune cells change in the blood of people with kidney or bladder cancer during immunotherapy treatment. Researchers will measure different immune cells and tumor cells in blood samples from 67 participants. The goal is to better understand how the immune system responds to these treatments, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients respond best to immunotherapy for kidney and bladder cancers.
- What could go wrong
- This is a small pilot study focused on observation, not treatment. It may not lead to immediate changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw may spot kidney cancer early
- Personalized vaccine trains immune system to attack kidney cancer blood vessels
- New kidney cancer drug shows promise in early trial
- New hope for advanced kidney cancer: belzutifan takes on everolimus in major trial
- New hope for advanced kidney cancer: Triple-Drug combo shows promise
- New drug cocktail aims to fight advanced cancers